Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
We performed a pairwise and network meta-analysis to compare pathological complete response (pCR) among neoadjuvant chemotherapy in patients with triple-negative breast cancer. We searched PubMed for randomized clinical trials between January 1, 2000 and December 1, 2020. Abstracts from meetings wer...
Guardado en:
Autores principales: | Zeng-Jie Weng MM, Sheng-Xi Wu MD, He-San Luo MD, Ze-Sen Du MM, Xu-Yuan Li MD, Jia-Zhou Lin MM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e7b4ba731d154531ab046b97966f0737 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FREQUENCY OF PATHOLOGICAL COMPLETE RESPONSE (PCR) IN PATIENTS OF TRIPLE NEGATIVE BREAST CANCER AFTER NEO-ADJUVANT CHEMOTHERAPY
por: Zeeshan Ahmed Khan Niazi, et al.
Publicado: (2021) -
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: Ana Julia Aguiar de Freitas, et al.
Publicado: (2021) -
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Nina Radosevic-Robin, et al.
Publicado: (2021) -
Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021) -
Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Yuki Usui, et al.
Publicado: (2021)